This review provides an overview of ticagrelor use in acute coronary syndromes, highlighting its role as a more potent alternative to clopidogrel.
May guide ticagrelor use in ACS; extends evidence synthesis but leaves open need for updated trials.
Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
No takes yet. Share an insight, caveat, or question.
Navarese et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: